Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis

Obstetrics and Gynecology

Volumn 126, Issue 3, 2015, Pages 617-627

  Di Vasta, Amy D ^a   Feldman, Henry A ^a   Sadler Gallagher, Jenny ^a   Stokes, Natalie A ^a   Laufer, Marc R ^a   Hornstein, Mark D ^a   Gordon, Catherine M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; LEUPRORELIN; NORETHISTERONE ACETATE; PLACEBO; GONADORELIN; NORETHISTERONE;

ABDOMINAL PAIN; ACNE; ADD ON THERAPY; ADOLESCENT; ADULT; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; FEMALE; HIP; HUMAN; LUMBAR SPINE; PELVIC PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; OSTEOLYSIS; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BONE DENSITY; BONE RESORPTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOMETRIOSIS; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; NORETHINDRONE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939623461     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000964     Document Type: Conference Paper

References (29)

1. Laufer MR, Goitein L, Bush M, Cramer DW, Emans SJ. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10: 199-202
2. Steingold KA, Cedars M, Lu JK, Randle D, Judd HL, Meldrum DR. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol 1987; 69: 403-11
3. Surrey ES. Gonadotropin-releasing hormone agonist and addback therapy: what do the data show?. Curr Opin Obstet Gynecol 2010; 22: 283-8
4. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91: 16-24
5. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992; 75: 558-63
6. Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis. Fertil Steril 2004; 81: 149-53
7. Revilla R, Revilla M, Hernández ER, Villa LF, Varela L, Rico H. Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered. Maturitas 1995; 22: 145-50
8. Surrey ES, Hornstein MD. Prolonged GnRH agonist and addback therapy for symptomatic endometriosis: long-term followup. Obstet Gynecol 2002; 99: 709-19
9. Kiesel L, Schweppe KW, Sillem M, Siebzehnrübl E. Should add-back therapy for endometriosis be deferred for optimal results?. Br J Obstet Gynaecol 1996; 103(suppl 14): 15-7
10. DiVasta AD, Gordon CM. Bone health in adolescents. Adolesc Med Clin 2006; 17: 639-52
11. Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. Pediatrics 2014; 134: e1229-43
12. Bonjour JP, Chevalley T. Pubertal timing, bone acquisition, and risk of fracture throughout life. Endocr Rev 2014; 35: 820-47
13. Endometriosis in adolescents. ACOG Committee Opinion No. 310. American College of Obstetricians and Gynecologists. Obstet Gynecol 2005; 105: 921-7
14. Becker CM, Laufer MR, Stratton P, Hummelshoj L, Missmer SA, Zondervan KT, et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: I. Surgical phenotype data collection in endometriosis research. Fertil Steril 2014; 102: 1213-22
15. Ware JE. SF-36 health survey update. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment. Vol. 3. 3rd ed. Mahwah (NJ): Lawrence Erlbaum Associates; 2004. p. 693-718
16. Beck AT, Brown G, Steer RA. Beck depression inventory II manual. San Antonio (TX): The Psychological Corporation; 1996
17. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric 2000; 3: 50-8
18. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30
19. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740-5
20. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007; 92: 2205-7
21. Gordon CM, Nelson LM. Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol 2003; 15: 377-84
22. Seeman E, Karlsson MK, Duan Y. On exposure to anorexia nervosa, the temporal variation in axial and appendicular skeletal development predisposes to site-specific deficits in bone size and density: a cross-sectional study. J Bone Miner Res 2000; 15: 2259-65
23. Gordon CM, Goodman E, Emans SJ, Grace E, Becker KA, Rosen CJ, et al. Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 2002; 141: 64-70
24. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-76
25. Liu SL, Lebrun CM. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br J Sports Med 2006; 40: 11-24
26. Gordon CM, Grace E, Emans SJ, Goodman E, Crawford MH, Leboff MS. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J Bone Miner Res 1999; 14: 136-45
27. Al-Omari WR, Nassir UN, Izzat B. Estrogen add-back and lipid profile during GnRH agonist (triptorelin) therapy. Int J Gynaecol Obstet 2001; 74: 61-2
28. Surrey ES, Fournet N, Voigt B, Judd HL. Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report. Obstet Gynecol 1993; 81: 581-6
29. Chevalley T, Bonjour JP, Ferrari S, Rizzoli R. The influence of pubertal timing on bone mass acquisition: a predetermined trajectory detectable five years before menarche. J Clin Endocrinol Metab 2009; 94: 3424-31